Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 59, Issue 5, 2012, Pages 925-927

  Merryman, Reid ^a   Stevenson, Kristen E ^b   Gostic, William J ^a   Neuberg, Donna ^b   O'Brien, Jane ^c   Sallan, Stephen E ^a,c   Silverman, Lewis B ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia (ALL); Asparaginase; Myelosuppression

Indexed keywords

ASPARAGINASE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASPARAGINASE ASSOCIATED MYELOSUPPRESSION; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; DRUG DOSE REDUCTION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION;

6-MERCAPTOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84866159972     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24182     Document Type: Article

References (9)

1. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24: 320-334.
2. Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009; 7: 600-606.
3. Oehlers MJ, Fetawadjieff W, Woodliff HJ. Profound leukopenia following asparaginase treatment in a patient with acute lymphoblastic leukaemia. Med J Aust 1969; 2: 907-909.
4. Kolarz G, Pietschmann H. Leukocyte alterations during asparaginase therapy. Wien Med Wschr 1971; 121: 196-199.
5. Lorie YI, Kruglova GV, Poddubnaia IV, et al. Investigations with L-asparaginase therapy in malignant hematologic diseases. Klin Med (Moskva) 1973; 51: 52-58.
6. Johnston PGB, Hardisty RM, Kay HEM, et al. Myelosuppressive effect of colaspase (L-asparaginase) in initial treatment of acute lymphoblastic leukaemia. Br Med J 1974; 3: 81-83.
7. Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007; 110: 1607-1611.
8. Salzer WL, Devidas M, Shuster JJ, et al. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: Report from the children's oncology group. J Pediatr Hematol Oncol 2007; 29: 369-375.
9. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A pediatric oncology group study. Leukemia 1999; 13: 335-342.